11 February 2026
Proveca announces exclusive worldwide development and license agreement with Catalent for its Zydis® ODT technology for use with Glycopyrrolate
This press release is intended for investors only. 10th February 2026 - Proveca, a pharmaceutical company specialising in medicines for children, announced today that it has entered into an exclusive worldwide development and license agreement with Catalent, a leading global...
21 January 2026
QV Bioelectronics receives £4.5m boost for implantable brain cancer therapy
A Cheshire-based medtech business has secured £4.5m of investment and grant funding to revolutionise treatment for the most common type of primary brain cancer in adults. The investment round was led by PXN Ventures, which launched following the merger between Praetura Ventures...